Results 11 to 20 of about 9,113,589 (351)
Immunotherapy of Crohn's disease
Mediators of Inflammation, 1998 Although the initiating events of Crohn's disease are unknown, models of experimental colitis have provided new insights in the immunologically mediated pathways of mucosal inflammation.
C. van Montfrans +2 more
doaj +6 more sources
Crohn's disease or Crohn's diseases? [PDF]
Gut, 2003 Disease behaviour in Crohn’s disease is dynamic and not stable over time In their landmark paper of 1932, Crohn, Ginzburg, and Oppenheimer1 described “a disease of the terminal ileum, affecting mainly young adults and characterised by a subacute or chronic necrotising and cicratrising inflammation.
Arnott, IDR, Satsangi, J
openaire +4 more sources
Medicine, 2003 Abstract Understanding the aetiology and pathogenesis of Crohn's disease remains a challenge, but it is clearly an interaction between the environment and a genetically susceptible individual. Multiple genes are being described, each contributing a small degree of susceptibility or protection, but the functional consequences of gene mutations are not ...
Gunnar Järnerot, Rune Sjödahl
openaire +5 more sources
Oral manifestations of Crohn's disease [PDF]
Stomatološki glasnik Srbije, 2004 Crohn's disease is a chronic granulomatous inflammatory bowel disease of unknown cause. Segments of the whole gastrointestinal tract may be involved, including the oral cavity.
Marković Ljiljana, Ljušković Bešir
doaj +1 more source
Knife cut fissures: A clue for vulval crohn's disease!!
Clinical Dermatology Review, 2021 Crohn's disease is an inflammatory bowel disorder with various extraintestinal manifestations. Vulva is rarely involved in Crohn's disease and occasionally may constitute the only sign of the disease.
M L Ranjitha +3 more
doaj +1 more source
Infliximab, azathioprine, or combination therapy for Crohn's disease.
New England Journal of Medicine, 2010 BACKGROUND The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease are unknown. METHODS In this randomized, double-blind trial, we evaluated the efficacy of infliximab monotherapy ...
J. Colombel +12 more
semanticscholar +1 more source
The Lancet, 2012 Crohn's disease is a relapsing systemic inflammatory disease, mainly affecting the gastrointestinal tract with extraintestinal manifestations and associated immune disorders. Genome wide association studies identified susceptibility loci that--triggered by environmental factors--result in a disturbed innate (ie, disturbed intestinal barrier, Paneth ...
William J. Sandborn, Daniel C. Baumgart
openaire +3 more sources
Ileal and colonic Crohn's disease: Does location makes a difference in therapy efficacy?
Current Research in Pharmacology and Drug Discovery, 2022 Within the IBD entity of Crohn's disease, there is currently no differentiation between ileal and colonic manifestation for recruitment of patients in clinical trials, well-powered analysis of study results or therapeutic decisions in daily clinical ...
Raja Atreya +5 more
doaj
Where are all the Mycobacterium avium subspecies paratuberculosis in patients with Crohn's disease?
PLoS Pathogens, 2009 Mycobacterium avium subspecies paratuberculosis (MAP) causes a chronic granulomatous inflammation of the intestines, Johne's disease, in dairy cows and every other species of mammal in which it has been identified.
Ellen S Pierce
doaj +1 more source